EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Optimizing the patient journey: Insights from early implementation of long‐acting cabotegravir and rilpivirine in four urban Ryan White‐funded clinics in the United States

Xavier A Erguera, Mollie B Smith, Priyasha Pareek, Alicia Dawdani, Kaylin V Dance, Ryan S Walker, Janet Grochowski, Jon Oskarsson, Matthew D Hickey, Mallory O Johnson, John Sauceda, Jose I Gutierrez und 6 weitere

Journal of the International AIDS Society · 2026

DOI: 10.1002/jia2.70082 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the International AIDS Society, 2026. Verfasst von Xavier A Erguera und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: HIV Infections, Rilpivirine, Pyridones, Anti-HIV Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LFC, Lake Forest College.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Long‐acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) represents a breakthrough in HIV treatment. However, understanding how to optimize real‐world service delivery and user experiences among people with HIV (PWH) remains limited.

Methods

Between August 2022 and December 2024, we conducted semi‐structured interviews with PWH at four academic Ryan White‐funded HIV clinics in Atlanta, Chicago and San Francisco. Eligibility criteria were current LAI‐CAB/RPV use with ≥3 injections or having discontinued. Interviews were analysed using thematic analysis grounded in descriptive phenomenology.

Results

Among 69 participants, 48 of whom were receiving LAI‐CAB/RPV and 21 who had discontinued, we identified three themes that highlighted opportunities to enhance patient‐centred service delivery of LAI‐CAB/RPV: (1) enhancing knowledge and self‐efficacy in using oral antiretroviral therapy (ART) in cases of missed or late injections; (2) improving patient comfort and confidence, particularly regarding injection anxiety, pain management and blood draws; (3) attending to the potential evolution of patient‐provider relationships, as in most cases injection visits outnumber primary care visits. In addition, PWH may experience depressive feelings upon discontinuation, even if they view it as the right decision.

Conclusions

Optimizing the LAI‐CAB/RPV patient journey requires developing a specialized support framework that is distinct from oral ART protocols. This new treatment modality requires a tailored approach that addresses unique challenges, including facilitating candid discussions about adherence contingencies, managing the physical and psychological aspects of injection experiences, ensuring meaningful and consistent provider relationships amid changing care patterns and providing enhanced support during treatment transitions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsRilpivirinePyridonesAnti-HIV AgentsHumansFemaleUnited StatesMaleAdultMiddle AgedDiketopiperazines

Stichwörter der Autor:innen

HIV acquisitionanxietycabotegravirpain managementpatient‐centred carerilpivirine

Substanzen

cabotegravirRilpivirinePyridonesAnti-HIV AgentsDiketopiperazines

Autor:innen und Institutionen

  • Department of Medicine, University of California San Francisco, San Francisco, California, USA.
  • University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA.
  • Department of Medicine, Emory University, Atlanta, Georgia, USA.
  • Department of Medicine, University of Chicago, Chicago, Illinois, USA.
  • Ponce de Leon Center, Grady Health System, Atlanta, Georgia, USA.
  • Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.

Förderung

  • LFC
  • Lake Forest College

Zitieren

APA

Erguera, X. A., Smith, M. B., Pareek, P., Dawdani, A., Dance, K. V., Walker, R. S., Grochowski, J., Oskarsson, J., Hickey, M. D., Johnson, M. O., Sauceda, J., Gutierrez, J. I., Montgomery, E. T., Colasanti, J. A., Collins, L. F., McNulty, M. C., Koester, K. A., & Christopoulos, K. A. (2026). Optimizing the patient journey: Insights from early implementation of long‐acting cabotegravir and rilpivirine in four urban Ryan White‐funded clinics in the United States. Journal of the International AIDS Society. https://doi.org/10.1002/jia2.70082

Vancouver

Erguera XA, Smith MB, Pareek P, Dawdani A, Dance KV, Walker RS, et al. Optimizing the patient journey: Insights from early implementation of long‐acting cabotegravir and rilpivirine in four urban Ryan White‐funded clinics in the United States. Journal of the International AIDS Society. 2026. doi:10.1002/jia2.70082

BibTeX
@article{Erguera2026,
  author = {Erguera, Xavier A and Smith, Mollie B and Pareek, Priyasha and Dawdani, Alicia and Dance, Kaylin V and Walker, Ryan S and Grochowski, Janet and Oskarsson, Jon and Hickey, Matthew D and Johnson, Mallory O and Sauceda, John and Gutierrez, Jose I and Montgomery, Elizabeth T and Colasanti, Jonathan A and Collins, Lauren F and McNulty, Moira C and Koester, Kimberly A and Christopoulos, Katerina A},
  title = {Optimizing the patient journey: Insights from early implementation of long‐acting cabotegravir and rilpivirine in four urban Ryan White‐funded clinics in the United States},
  journal = {Journal of the International AIDS Society},
  year = {2026},
  doi = {10.1002/jia2.70082}
}
Kostenlos starten →